AbbVie Gets EU OK of VENCLYXTO + Rituximab for Lymphocytic Leukemia

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC) has approved the type-II variation application for VENCLYXTO^® (venetoclax) in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who have received at least one prior therapy. This approval allows more patients to receive VENCLYXTO in the second-line setting and gives healthcare providers the ability to prescribe this medicine to a broader population of patients with R/R CLL than the previously approved indication for VENCLYXTO as monotherapy in the European Union (EU). The approval is valid in all 28 member states of the EU, as well as Iceland, Liechtenstein and Norway.

https://www.biospace.com/article/releases/abbvie-receives-european-commission-approval-of-venclyxto-venetoclax-plus-rituximab-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia-who-have-received-at-least-one-prior-therapy/